Skip Navigation

David P. Steensma, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Senior Physician
  • Associate Professor of Medicine, Harvard Medical School

Clinical Interests

  • Myelodysplastic syndromes

Contact Information

  • Appointments617-789-2903
  • Office Phone Number617-632-3712 (Boston main campus)
    617-789-2903 (St. Elizabeths)
  • Fax617-582-7840 (Boston main campus)
    617-789-2064 (St. Elizabeths)

Board Certification:

  • Hematology , 2002
  • Internal Medicine , 1999
  • Medical Oncology , 2003

Fellowship:

  • Institute of Molecular Medicine, University of Oxford
  • Mayo Clinic, Hematology/Oncology

Residency:

  • Mayo Clinic

Medical School:

  • University of Chicago Pritzker School of Medicine

Recent Awards:

  • Fellowship, American College of Physicians 2006
  • Hematology/Oncology Teacher of The Year Finalist, Mayo Clinic 2007, 2008

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston MA, 02215
Get Directions

Dana-Farber Cancer Institute at St. Elizabeth's Medical Center
736 Cambridge Street
Brighton MA, 02135
Get Directions

Research

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018 Feb; 5(2):e63-e72.
View in: PubMed

Ghobrial IM, Detappe A, Anderson KC, Steensma DP. The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018 Jan 09.
View in: PubMed

Afshar A, Steensma DP, Kyle RA. Álvaro Alvim-Radiologist and Brazilian "Martyr to Science". Mayo Clin Proc. 2018 Jan; 93(1):e7.
View in: PubMed

Nazha A, Sekeres MA, Komrokji R, Steensma DP, Kantarjian H, Roboz G, Fenaux P, Prebet T, Azarnia N, Zbyszewski PS, Fruchtman SM, Santini V, Silverman LR, Platzbecker U, Garcia-Manero G. Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer J. 2017 Dec 14; 7(12):644.
View in: PubMed

Steensma DP. The Raven. J Clin Oncol. 2018 Feb 10; 36(5):512-513.
View in: PubMed

DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 Feb; 93(2):254-261.
View in: PubMed

Siddiqui S, Steensma DP, Kyle RA. Thalassemia and Thomas Benton Cooley. Mayo Clin Proc. 2017 Nov; 92(11):e161-e162.
View in: PubMed

Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017 Oct 24; 1(23):2032-2040.
View in: PubMed

Steensma DP. The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes. Best Pract Res Clin Haematol. 2017 Dec; 30(4):295-300.
View in: PubMed

Morgan EA, Lee MN, DeAngelo DJ, Steensma DP, Stone RM, Kuo FC, Aster JC, Gibson CJ, Lindsley RC. Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Adv. 2017 Sep 26; 1(21):1786-1789.
View in: PubMed

Steensma DP, Kyle RA. Charles Fletcher, The Centaur Company, and Proprietary Medicine Revenue Stamps. Mayo Clin Proc. 2017 Sep; 92(9):e127-e128.
View in: PubMed

Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017 09 28; 130(13):1514-1522.
View in: PubMed

Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer. 2017 Oct 01; 123(19):3662-3672.
View in: PubMed

Zeidan AM, Sekeres MA, Barnard J, Steensma DP, Komrokji R. Therapy-related myelodysplastic syndromes-specific risk stratification: are we putting the cart before the horse? Leukemia. 2017 Nov; 31(11):2539-2541.
View in: PubMed

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017 Sep 26; 8(43):73483-73500.
View in: PubMed

Afshar A, Kyle RA, Steensma DP. Adolf Lorenz - The Bloodless Surgeon of Vienna. Mayo Clin Proc. 2017 Jul; 92(7):e105-e106.
View in: PubMed

Afshar A, Steensma DP, Kyle RA. Antonius Mathijsen and Plaster Casts. Mayo Clin Proc. 2017 May; 92(5):e83.
View in: PubMed

Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, Santini V, Sekeres MA, Balleari E, Kaivers J, Sapena R, Götze K, Müller-Thomas C, Beyne-Rauzy O, Stamatoullas A, Kotsianidis I, Komrokji R, Steensma DP, Fensterl J, Roboz GJ, Bernal T, Ramos F, Calabuig M, Guerci-Bresler A, Bordessoule D, Cony-Makhoul P, Cheze S, Wattel E, Rose C, Vey N, Gioia D, Ferrero D, Gaidano G, Cametti G, Pane F, Sanna A, Germing U, Sanz GF, Dreyfus F, Fenaux P. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. J Clin Oncol. 2017 May 10; 35(14):1591-1597.
View in: PubMed

Luskin MR, Cronin AM, Owens RL, DeAngelo DJ, Stone RM, Wadleigh M, Steensma DP, Abel GA. Self-reported sleep disturbance and survival in myelodysplastic syndromes. Br J Haematol. 2017 05; 177(4):562-566.
View in: PubMed

Steensma DP. The origin and evolution of the term "clone". Leuk Res. 2017 Jun; 57:97-101.
View in: PubMed

Kuo FC, Steensma DP, Dal Cin P. Conventional cytogenetics for myeloid neoplasms in the era of next-generation-sequencing. Am J Hematol. 2017 Mar; 92(3):227-229.
View in: PubMed

Steensma DP, Kyle RA. Van Gogh's Portrait of Dr Gachet. Mayo Clin Proc. 2017 Mar; 92(3):e57-e58.
View in: PubMed

Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern A, Roboz G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia. 2017 Jun; 31(6):1391-1397.
View in: PubMed

Steensma DP, Kyle RA. The Medical Doctors of Star Trek: Leonard "Bones" McCoy and Beverly Crusher. Mayo Clin Proc. 2017 Jan; 92(1):e9-e10.
View in: PubMed

Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 Dec 07; 8(368):368ra171.
View in: PubMed

Steensma DP. Predicting therapy-related myeloid neoplasms-and preventing them? Lancet Oncol. 2017 Jan; 18(1):11-13.
View in: PubMed

Steensma DP. New challenges in evaluating anemia in older persons in the era of molecular testing. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):67-73.
View in: PubMed

Steensma DP, Kyle RA. Hendrik van Deventer: Dutch Obstetrician and Orthopedist. Mayo Clin Proc. 2016 Dec; 91(12):e171.
View in: PubMed

Brierley CK, Steensma DP. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms. Curr Hematol Malig Rep. 2016 Dec; 11(6):408-415.
View in: PubMed

Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion. 2017 Feb; 57(2):289-295.
View in: PubMed

DeZern AE, Zeidan AM, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, Sekeres MA. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC). Leuk Lymphoma. 2017 Jun; 58(6):1325-1331.
View in: PubMed

Zeidan AM, Xu M, Steensma DP. The importance of erythroblast enumeration in myeloid neoplasia. Ann Hematol. 2017 Feb; 96(2):329-330.
View in: PubMed

Steensma DP. Good riddance to the term "refractory anemia" in myelodysplastic syndromes. Leuk Res. 2016 Dec; 51:22-26.
View in: PubMed

Ruiz-Argüelles GJ, Steensma DP. Staunching the rising costs of haematological health care. Lancet Haematol. 2016 Oct; 3(10):e455.
View in: PubMed

Steensma DP. Putting it all together in CMML risk stratification. Blood. 2016 09 08; 128(10):1318-9.
View in: PubMed

Bhatt VR, Steensma DP. Hematopoietic Cell Transplantation for Myelodysplastic Syndromes. J Oncol Pract. 2016 Sep; 12(9):786-92.
View in: PubMed

Steensma DP, Kyle RA, Shampo MA. J. Robin Warren: Helicobacter Pylori and Peptic Ulcer. Mayo Clin Proc. 2016 Sep; 91(9):e129-30.
View in: PubMed

Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer. 2016 08 19; 16:652.
View in: PubMed

Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RP. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol. 2016 Oct; 29(10):1221-31.
View in: PubMed

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

Brunner AM, Steensma DP. Myelodysplastic syndrome associated with acquired beta thalassemia: "BTMDS". Am J Hematol. 2016 08; 91(8):E325-7.
View in: PubMed

Steensma DP, Kyle RA, Shampo MA. Elizabeth Blackburn and Maintenance of Telomeres. Mayo Clin Proc. 2016 07; 91(7):e105.
View in: PubMed

Wolach O, Stevenson KE, Wadleigh M, DeAngelo DJ, Steensma DP, Ballen KK, Soiffer RJ, Antin JH, Neuberg DS, Ho VT, Stone RM. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 Aug; 91(8):793-9.
View in: PubMed

El-Jawahri A, Keenan T, Abel GA, Steensma DP, LeBlanc TW, Chen YB, Hobbs G, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Ballen KK, Amrein PC, Stone RM, Temel JS. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
View in: PubMed

Fathi AT, DeAngelo DJ, Stevenson KE, Kolitz JE, Asch JD, Amrein PC, Attar EC, Steensma DP, Wadleigh M, Foster J, Connolly C, Galinsky I, Devoe CE, Stone RM, Neuberg DS, Ballen KK. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88.
View in: PubMed

Kyle RA, Steensma DP, Shampo MA. Barry James Marshall-Discovery of Helicobacter pylori as a Cause of Peptic Ulcer. Mayo Clin Proc. 2016 05; 91(5):e67-8.
View in: PubMed

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Ann Hematol. 2016 Jun; 95(7):1197-200.
View in: PubMed

Roberts DA, Kantarjian HM, Steensma DP. Contract research organizations in oncology clinical research: Challenges and opportunities. Cancer. 2016 May 15; 122(10):1476-82.
View in: PubMed

El-Jawahri A, Kim HT, Steensma DP, Cronin AM, Stone RM, Watts CD, Chen YB, Cutler CS, Soiffer RJ, Abel GA. Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016 Aug; 51(8):1121-6.
View in: PubMed

Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA. The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica. 2016 06; 101(6):e224-7.
View in: PubMed

Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508.
View in: PubMed

Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematologica. 2016 06; 101(6):781-8.
View in: PubMed

Brierley CK, Steensma DP. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter? Curr Opin Hematol. 2016 Mar; 23(2):167-74.
View in: PubMed

Kyle RA, Steensma DP, Shampo MA. Otto Wichterle--Inventor of the First Soft Contact Lenses. Mayo Clin Proc. 2016 Mar; 91(3):e45-6.
View in: PubMed

Abel GA, Cronin AM, Odejide OO, Uno H, Stone RM, Steensma DP. Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes. Br J Haematol. 2016 06; 173(5):713-21.
View in: PubMed

Jain N, Steensma D, Stewart DJ, Kantarjian H. Insurance Denial of Coverage for Patients Enrolled in Cancer Clinical Trials Is Still a Problem in the Affordable Care Act Era. J Oncol Pract. 2016 Apr; 12(4):283-5.
View in: PubMed

Fletcher SA, Cronin AM, Zeidan AM, Odejide OO, Gore SD, Davidoff AJ, Steensma DP, Abel GA. Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer. 2016 Apr 15; 122(8):1209-15.
View in: PubMed

Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS. A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML). Clin Cancer Res. 2016 Aug 01; 22(15):3746-54.
View in: PubMed

Steensma DP. The Farid Fata Medicare Fraud Case and Misplaced Incentives in Oncology Care. J Oncol Pract. 2016 Jan; 12(1):51-4.
View in: PubMed

Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents. Leuk Res. 2016 Feb; 41:43-7.
View in: PubMed

Kyle RA, Steensma DP, Shampo MA. Friedrich August Johannes Löffler (Loeffler), German Bacteriologist. Mayo Clin Proc. 2015 Dec; 90(12):e135.
View in: PubMed

Steensma DP. Cytopenias + mutations - dysplasia = what? Blood. 2015 Nov 19; 126(21):2349-51.
View in: PubMed

Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS. Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? Am J Hematol. 2015 Nov; 90(11):1036-40.
View in: PubMed

Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2016 Mar; 30(3):649-57.
View in: PubMed

Keenan T, Abel GA, Steensma DP, LeBlanc TW, Traeger L, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs G, Amrein PC, Stone RM, Ballen KK, Chen YA, Temel JS. Potentially avoidable hospitalizations in older patients with acute myeloid leukemia (AML). J Clin Oncol. 2015 Oct 10; 33(29_suppl):206.
View in: PubMed

Cronin A, Watts CD, Steensma DP, Stone RM, DeAngelo DJ, Owens RL, Wadleigh M, Abel GA. Impact of sleep disturbance in myelodysplastic syndromes (MDS). J Clin Oncol. 2015 Oct 10; 33(29_suppl):99.
View in: PubMed

Steensma DP. Graphical representation of clinical outcomes for patients with myelodysplastic syndromes. Leuk Lymphoma. 2016; 57(1):17-20.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. Ernesto "Che" Guevara de la Serna: Argentinian Marxist Revolutionary. Mayo Clin Proc. 2015 Oct; 90(10):e111-2.
View in: PubMed

Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. J Am Coll Cardiol. 2015 Sep 08; 66(10):1160-78.
View in: PubMed

Roberts DA, Steensma DP. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents. Curr Hematol Malig Rep. 2015 Sep; 10(3):318-28.
View in: PubMed

Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF, Nikcevich D, Loprinzi CL. A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. Am J Hematol. 2015 Oct; 90(10):877-81.
View in: PubMed

Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better? Am J Hematol. 2015 Aug 11.
View in: PubMed

Steensma DP. Key Opinion Leaders. J Clin Oncol. 2015 Oct 01; 33(28):3213-4.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. Max Perutz and the Structure of Hemoglobin. Mayo Clin Proc. 2015 Aug; 90(8):e89.
View in: PubMed

Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
View in: PubMed

Jones GH, Tefferi A, Steensma D, Kantarjian H. The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015. Am J Med. 2015 Nov; 128(11):1162-4.
View in: PubMed

Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, Christie AL, Liu H, Christodoulou A, van Bodegom D, van der Zwet J, Layer JV, Tivey T, Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D, Wadleigh M, Harris M, Mandon E, Ebel N, Andraos R, Romanet V, Dölemeyer A, Sterker D, Zender M, Rodig SJ, Murakami M, Hofmann F, Kuo F, Eck MJ, Silverman LB, Sallan SE, Letai A, Baffert F, Vangrevelinghe E, Radimerski T, Gaul C, Weinstock DM. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
View in: PubMed

Steensma DP. Myelodysplastic Syndromes: Diagnosis and Treatment. Mayo Clin Proc. 2015 Jul; 90(7):969-83.
View in: PubMed

Fega KR, Abel GA, Motyckova G, Sherman AE, DeAngelo DJ, Steensma DP, Galinsky I, Wadleigh M, Stone RM, Driver JA. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015 Jul; 6(4):288-98.
View in: PubMed

Steensma DP, Sasu BJ, Sloan JA, Tomita DK, Loprinzi CL. Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Blood. 2015 Jun 04; 125(23):3669-71.
View in: PubMed

Kyle RA, Steensma DP, Shampo MA. Howard Walter Florey-Production of Penicillin. Mayo Clin Proc. 2015 Jun; 90(6):e63-4.
View in: PubMed

Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 Jul 02; 126(1):9-16.
View in: PubMed

El-Jawahri AR, Abel GA, Steensma DP, LeBlanc TW, Fathi AT, Graubert TA, DeAngelo DJ, Wadleigh M, Ballen KK, Foster JE, Attar EC, Amrein PC, Brunner AM, Stone RM, Temel JS. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. John E. Walker—Nobel Prize in chemistry in 1997. Mayo Clin Proc. 2015 Apr; 90(4):e41.
View in: PubMed

Steensma DP. Speaking a common language in MDS/MPNs. Blood. 2015 Mar 19; 125(12):1849-51.
View in: PubMed

Steensma DP. Mimicking MacGyver in the oncology clinic: improvisation and creative solutions, only rarely involving duct tape. J Natl Compr Canc Netw. 2015 Mar; 13(3):371-3.
View in: PubMed

Padron E, Steensma DP. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies. Curr Opin Hematol. 2015 Mar; 22(2):163-70.
View in: PubMed

Sankaran VG, Ulirsch JC, Tchaikovskii V, Ludwig LS, Wakabayashi A, Kadirvel S, Lindsley RC, Bejar R, Shi J, Lovitch SB, Bishop DF, Steensma DP. X-linked macrocytic dyserythropoietic anemia in females with an ALAS2 mutation. J Clin Invest. 2015 Apr; 125(4):1665-9.
View in: PubMed

Brierley CK, Steensma DP. Thrombopoiesis-stimulating agents and myelodysplastic syndromes. Br J Haematol. 2015 May; 169(3):309-23.
View in: PubMed

Kyle RA, Steensma DP, Shampo MA. Oscar (Oskar) Minkowski: discovery of the pancreatic origin of diabetes. Mayo Clin Proc. 2015 Feb; 90(2):e17-8.
View in: PubMed

Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, Neuberg D, Stone RM, Ebert BL. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015 Feb 26; 125(9):1367-76.
View in: PubMed

Roberts DA, Wadleigh M, McDonnell AM, DeAngelo DJ, Stone RM, Steensma DP. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2015 Feb; 39(2):204-10.
View in: PubMed

Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 Mar 15; 121(6):876-82.
View in: PubMed

Dumitrascu DL, Shampo M, Kyle RA, Steensma DP. Stamp vignette on medical science. Nicolae Testemitanu-Moldovan surgeon, scientist, and politician. Mayo Clin Proc. 2014 Dec; 89(12):e131.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. Bruce Beutler: innate immunity and Toll-like receptors. Mayo Clin Proc. 2014 Oct; 89(10):e101.
View in: PubMed

Bejar R, Steensma DP. Recent developments in myelodysplastic syndromes. Blood. 2014 Oct 30; 124(18):2793-803.
View in: PubMed

Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, Neuberg D, Steensma DP, Ebert BL. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 Oct 23; 124(17):2705-12.
View in: PubMed

Freireich EJ, Wiernik PH, Steensma DP. The leukemias: a half-century of discovery. J Clin Oncol. 2014 Nov 01; 32(31):3463-9.
View in: PubMed

Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea E, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
View in: PubMed

Steensma DP, Rayson D, Shampo MA, Kyle RA. Terry Fox: Canadian cancer research activist whose "Marathon of Hope" inspired millions. Mayo Clin Proc. 2014 Aug; 89(8):e75-6.
View in: PubMed

Hasserjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, Cascio MJ, Rogers HJ, Hsi ED, Soderquist C, Bagg A, Yan J, Ochs R, Orazi A, Moore F, Mahmoud A, George TI, Foucar K, Odem J, Booth C, Morice W, DeAngelo DJ, Steensma D, Stone RM, Neuberg D, Arber DA. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with =30% blasts in older adults: a Bone Marrow Pathology Group study. Am J Hematol. 2014 Nov; 89(11):E193-9.
View in: PubMed

Steensma DP, Kantarjian HM. Reply to J.S. Abrams et al. J Clin Oncol. 2014 Aug 10; 32(23):2516.
View in: PubMed

Garcia-Manero G, Gartenberg G, Steensma DP, Schipperus MR, Breems DA, de Paz R, Valcárcel D, Kranenburg B, Reddy M, Komrokji RS. A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome. Am J Hematol. 2014 Sep; 89(9):E156-62.
View in: PubMed

Steensma DP, Montori VM, Shampo MA, Kyle RA. Stamp vignette on medical science. Daniel Alcides Carrión--Peruvian hero and medical martyr. Mayo Clin Proc. 2014 Jun; 89(6):e55-6.
View in: PubMed

Kantarjian H, Steensma D, Rius Sanjuan J, Elshaug A, Light D. High cancer drug prices in the United States: reasons and proposed solutions. J Oncol Pract. 2014 Jul; 10(4):e208-11.
View in: PubMed

Gafter-Gvili A, Steensma DP, Auerbach M. Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated? J Natl Compr Canc Netw. 2014 May; 12(5):657-64.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. Physician-poet William Carlos Williams--"no ideas but in things". Mayo Clin Proc. 2014 Apr; 89(4):e35-6.
View in: PubMed

Kantarjian HM, Steensma DP, Light DW. The Patient Protection and Affordable Care Act: Is it good or bad for oncology? Cancer. 2014 Jun 01; 120(11):1600-3.
View in: PubMed

Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, Dennison B, Sekeres MA. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014 Jun 01; 120(11):1670-6.
View in: PubMed

Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD. NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood. 2014 May 01; 123(18):2816-25.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. Wilberforce J. J. Arnold--"St. Helena's Greatest Friend". Mayo Clin Proc. 2014 Feb; 89(2):e15.
View in: PubMed

Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, Efficace F. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood. 2014 Jan 16; 123(3):451-2.
View in: PubMed

Steensma DP, Kantarjian HM. Impact of cancer research bureaucracy on innovation, costs, and patient care. J Clin Oncol. 2014 Feb 10; 32(5):376-8.
View in: PubMed

McCarthy JT, Hocum CL, Albright RC, Rogers J, Gallaher EJ, Steensma DP, Gudgell SF, Bergstralh EJ, Dillon JC, Hickson LJ, Williams AW, Dingli D. Biomedical system dynamics to improve anemia control with darbepoetin alfa in long-term hemodialysis patients. Mayo Clin Proc. 2014 Jan; 89(1):87-94.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. The 1964 "Doctors Mayo" commemorative postage stamp. Mayo Clin Proc. 2014 Jan; 89(1):e1-2.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Alois Alzheimer--Alzheimer disease. Mayo Clin Proc. 2013 Dec; 88(12):e155.
View in: PubMed

Kantarjian H, Steensma D, Light D. Should oncologists support the Affordable Care Act? Lancet Oncol. 2013 Dec; 14(13):1258-9.
View in: PubMed

Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res. 2014 Mar 01; 20(5):1135-45.
View in: PubMed

Bowen DT, Hellström-Lindberg E, Steensma DP. Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol. 2014 Feb; 164(4):610-1.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. James B. Collip--member of the Canadian team that isolated insulin. Mayo Clin Proc. 2013 Nov; 88(11):e139-40.
View in: PubMed

Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MAS, Scadden DT, Schreiber SL, Ebert BL, Golub TR. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol. 2013 Dec; 9(12):840-848.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. Michael Servetus: unorthodox theologian, meticulous cartographer, and innovative anatomist. Mayo Clin Proc. 2013 Oct; 88(10):e119-20.
View in: PubMed

Steensma DP, Gattermann N. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes? Best Pract Res Clin Haematol. 2013 Dec; 26(4):431-44.
View in: PubMed

Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M. Myeloid growth factors. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1266-90.
View in: PubMed

Ramsey H, Zhang Q, Brown DE, Steensma DP, Lin CP, Wu MX. Stress-induced hematopoietic failure in the absence of immediate early response gene X-1 (IEX-1, IER3). Haematologica. 2014 Feb; 99(2):282-91.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Stamp vignette on medical science. Vincent du Vigneaud-Nobel Prize in chemistry. Mayo Clin Proc. 2013 Sep; 88(9):e99.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Tadeus Reichstein-work on hormones of the adrenal glands. Mayo Clin Proc. 2013 Aug; 88(8):e85.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. John Robert Vane--British pharmacologist and Nobel laureate. Mayo Clin Proc. 2013 Jul; 88(7):e71.
View in: PubMed

Attar EC, Amrein PC, Fraser JW, Fathi AT, McAfee S, Wadleigh M, Deangelo DJ, Steensma DP, Stone RM, Foster J, Neuberg D, Ballen KK. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20.
View in: PubMed

Sherman AE, Motyckova G, Fega KR, Deangelo DJ, Abel GA, Steensma D, Wadleigh M, Stone RM, Driver JA. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res. 2013 Sep; 37(9):998-1003.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Jens Skou--nobel prize in chemistry. Mayo Clin Proc. 2013 Jun; 88(6):e55.
View in: PubMed

Steensma DP, Ebert BL. Initial experience with L-leucine therapy in myelodysplastic syndromes with associated chromosome 5q deletion. Blood. 2013 May 23; 121(21):4428.
View in: PubMed

Steensma DP, Sekeres MA. Reply to H. Kantarjian et al. J Clin Oncol. 2013 May 10; 31(14):1796.
View in: PubMed

Steensma DP. The beginning of the end of the beginning in cancer genomics. N Engl J Med. 2013 May 30; 368(22):2138-40.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Ian Wilmut--pioneer of cloning. Mayo Clin Proc. 2013 May; 88(5):e41.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Horace Magoun--neuroanatomist and neurophysiologist. Mayo Clin Proc. 2013 Apr; 88(4):e33.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Hermann staudinger-founder of polymer chemistry. Mayo Clin Proc. 2013 Mar; 88(3):e23.
View in: PubMed

Tothova Z, Steensma DP, Ebert BL. New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res. 2013 Apr 01; 19(7):1637-43.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Elias James Corey--Nobel Prize for retrosynthetic analysis. Mayo Clin Proc. 2013 Jan; 88(1):e7.
View in: PubMed

Steensma DP. Stories we tell one another: narrative reflection and the art of oncology. Am Soc Clin Oncol Educ Book. 2013.
View in: PubMed

Steensma DP. Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. Curr Hematol Malig Rep. 2012 Dec; 7(4):310-20.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Richard Ernst--Nobel Prize for nuclear magnetic resonance spectroscopy. Mayo Clin Proc. 2012 Dec; 87(12):e109.
View in: PubMed

Steensma DP, Viprakasit V, Kyle RA, Shampo MA. Prince Wongsa Dhiraj Snid--Thai physician and diplomat. Mayo Clin Proc. 2012 Nov; 87(11):e93.
View in: PubMed

Brierley CK, Morgan EA, Sprague JR, Odejide OO, DeAngelo DJ, Steensma DP. An extreme example of focal bone marrow involvement in acute myeloid leukemia. Am J Hematol. 2013 Apr; 88(4):335-6.
View in: PubMed

Steensma DP. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes? Best Pract Res Clin Haematol. 2012 Dec; 25(4):443-51.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Sidney Altman--Nobel laureate for work with RNA. Mayo Clin Proc. 2012 Oct; 87(10):e73.
View in: PubMed

Sekeres MA, Steensma DP. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia. J Clin Oncol. 2012 Nov 20; 30(33):4061-3.
View in: PubMed

Kyle RA, Shampo MA, Steensma DP. Sir Brian Gerald Barratt-Boyes-pioneer cardiac surgeon. Mayo Clin Proc. 2012 Sep; 87(9):e65.
View in: PubMed

Steensma DP. Historical perspectives on myelodysplastic syndromes. Leuk Res. 2012 Dec; 36(12):1441-52.
View in: PubMed

Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012 Sep 20; 30(27):3376-82.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Catherine Verfaillie--stem cell researcher. Mayo Clin Proc. 2012 Aug; 87(8):e59.
View in: PubMed

Ruiz-Argüelles GJ, Gomez-Almaguer D, Steensma DP. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. Am J Hematol. 2012 Sep; 87(9):941.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. William Shockley and the transistor. Mayo Clin Proc. 2012 Jun; 87(6):e43.
View in: PubMed

Steensma DP. Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes. Biol Blood Marrow Transplant. 2012 Aug; 18(8):1145-7.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Charles F. Kettering-medical philanthropist and inventor. Mayo Clin Proc. 2012 May; 87(5):e35.
View in: PubMed

Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS). J Hematol Oncol. 2012 Apr 30; 5:18.
View in: PubMed

List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012 Jun 10; 30(17):2134-9.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Adolf Butenandt--Nobel Prize for chemistry. Mayo Clin Proc. 2012 Apr; 87(4):e27.
View in: PubMed

Jacobsen PB, Holland JC, Steensma DP. Caring for the whole patient: the science of psychosocial care. J Clin Oncol. 2012 Apr 10; 30(11):1151-3.
View in: PubMed

Motyckova G, Steensma DP. Why does my patient have lymphadenopathy or splenomegaly? Hematol Oncol Clin North Am. 2012 Apr; 26(2):395-408, ix.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Alexander Todd--British Nobel laureate. Mayo Clin Proc. 2012 Mar; 87(3):e19.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Isidor Rabi-1944 Nobel laureate in physics. Mayo Clin Proc. 2012 Feb; 87(2):e11.
View in: PubMed

Costanzi C, Bourdette D, Parisi JE, Woltjer R, Rodriguez F, Steensma D, Lucchinetti CF. Crystal-storing histiocytosis: An unusual relapsing inflammatory CNS disorder. Mult Scler Relat Disord. 2012 Apr; 1(2):95-9.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Nikolay Basov--nobel prize for lasers and masers. Mayo Clin Proc. 2012 Jan; 87(1):e3.
View in: PubMed

Steensma DP. Oddballs: acute leukemias of mixed phenotype and ambiguous origin. Hematol Oncol Clin North Am. 2011 Dec; 25(6):1235-53.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Hans Geiger-German physicist and the Geiger counter. Mayo Clin Proc. 2011 Dec; 86(12):e54.
View in: PubMed

Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, Steensma DP, Pardanani A, Hanson CA, Tefferi A. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012 Jan 12; 119(2):569-72.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Paul D. Boyer—Nobel prize for work on ATP synthase. Mayo Clin Proc. 2011 Nov; 86(11):e51.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Walter Hess—Nobel Prize for work on the brain. Mayo Clin Proc. 2011 Oct; 86(10):E49.
View in: PubMed

Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011 Oct; 38(5):635-47.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Charles Townes—nobel laureate for maser-laser work. Mayo Clin Proc. 2011 Sep; 86(9):e48.
View in: PubMed

Sekeres MA, Steensma DP. A piece of my mind. The road warriors. JAMA. 2011 Aug 24; 306(8):805-6.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Charles K. Kao—father of fiber optics. Mayo Clin Proc. 2011 Aug; 86(8):e45.
View in: PubMed

Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M. Myeloid growth factors. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):914-32.
View in: PubMed

Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 2011 Nov; 96(11):1619-26.
View in: PubMed

Steensma DP. Art of oncology: new voices wanted. J Clin Oncol. 2011 Sep 01; 29(25):3343-4.
View in: PubMed

Steensma DP, Stone RM. Lenalidomide in AML: del(5q) or who? Blood. 2011 Jul 21; 118(3):481-2.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Albert Sabin--conqueror of poliomyelitis. Mayo Clin Proc. 2011 Jul; 86(7):e44.
View in: PubMed

Steensma DP. The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. Curr Hematol Malig Rep. 2011 Jun; 6(2):136-44.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Frederick Soddy--pioneer in radioactivity. Mayo Clin Proc. 2011 Jun; 86(6):e39.
View in: PubMed

Steensma DP, Sasu BJ, Sloan JA, Tomita D, Loprinzi CL. The relationship between serum hepcidin levels and clinical outcomes in patients with chemotherapy-associated anemia treated in a controlled trial. J Clin Oncol. 2011 May 20; 29(15_suppl):9031.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Aleksandr Prokhorov--lasers and masers. Mayo Clin Proc. 2011 May; 86(5):e33.
View in: PubMed

Sekeres MA, Maciejewski JP, List AF, Steensma DP, Artz A, Swern AS, Scribner P, Huber J, Stone R. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. Oncologist. 2011; 16(6):904-11.
View in: PubMed

Baumann Kreuziger LM, Wolanskyj AP, Hanson CA, Steensma DP. Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts. Eur J Haematol. 2011 Jun; 86(6):512-6.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Susumu Tonegawa--Japan's first Nobel laureate in physiology or medicine. Mayo Clin Proc. 2011 Feb; 86(2):e14.
View in: PubMed

Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011 Jan; 86(1):96-8.
View in: PubMed

Kyle RA, Steensma DP. History of multiple myeloma. Recent Results Cancer Res. 2011; 183:3-23.
View in: PubMed

Steensma DP. The role of iron chelation therapy for patients with myelodysplastic syndromes. J Natl Compr Canc Netw. 2011 Jan; 9(1):65-75.
View in: PubMed

Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM, Novotny PJ, Loprinzi CL. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol. 2011 Jan 01; 29(1):97-105.
View in: PubMed

Steensma DP, Kyle RA, Shampo MA. Abbie Lathrop, the "mouse woman of Granby": rodent fancier and accidental genetics pioneer. Mayo Clin Proc. 2010 Nov; 85(11):e83.
View in: PubMed

Steensma DP, Kyle RA, Shampo MA. Walter Clement Noel—first patient described with sickle cell disease. Mayo Clin Proc. 2010 Oct; 85(10):e74-5.
View in: PubMed

Loprinzi CL, Schapira L, Moynihan T, Kalemkerian GP, von Gunten C, Steensma D. Compassionate honesty. J Palliat Med. 2010 Oct; 13(10):1187-91.
View in: PubMed

Davids MS, Steensma DP. The molecular pathogenesis of myelodysplastic syndromes. Cancer Biol Ther. 2010 Aug 15; 10(4):309-19.
View in: PubMed

Steensma DP. The scent of cancer. Ann Intern Med. 2010 Aug 03; 153(3):206-7.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Stamp vignette on medical science. Robert F. Curl Jr-Nobel Laureate in Chemistry. Mayo Clin Proc. 2010 Aug; 85(8):e58.
View in: PubMed

Steensma DP. A cello for Michayla. J Clin Oncol. 2010 Oct 01; 28(28):4400-1.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Edward L. Trudeau--founder of a sanatorium for treatment of tuberculosis. Mayo Clin Proc. 2010 Jul; 85(7):e48.
View in: PubMed

Steensma DP. P39/Tsugane cells are a false cell line contaminated with HL-60 cells and are not suitable for mechanistic studies in myelodysplastic syndromes. Haematologica. 2010 Jul; 95(7):1229-30.
View in: PubMed

Calvin AD, Somers VK, Steensma DP, Rio Perez JA, van der Walt C, Fitz-Gibbon JM, Scott CG, Olson LJ. Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin. Eur J Heart Fail. 2010 Apr; 12(4):354-9.
View in: PubMed

Steensma DP. Novel therapies for myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr; 24(2):423-41.
View in: PubMed

Steensma DP, Stone RM. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes. Hematol Oncol Clin North Am. 2010 Apr; 24(2):389-406.
View in: PubMed

Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP. Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol. 2010 Mar; 85(3):160-3.
View in: PubMed

Steensma DP. ACP Journal Club. Anemia was independently associated with mortality in very old persons. Ann Intern Med. 2009 Dec 15; 151(12):JC6-13.
View in: PubMed

Steensma DP. Decitabine treatment of patients with higher-risk myelodysplastic syndromes. Leuk Res. 2009 Dec; 33 Suppl 2:S12-7.
View in: PubMed

Savica R, Grossardt BR, Carlin JM, Icen M, Bower JH, Ahlskog JE, Maraganore DM, Steensma DP, Rocca WA. Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology. 2009 Oct 27; 73(17):1381-7.
View in: PubMed

Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila R, Kumar R, Ketterling RP. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Res. 2009 Oct 01; 69(19):7518-23.
View in: PubMed

Steensma DP. Out of this nettle, danger, we must pluck this flower, safety. Blood. 2009 Sep 17; 114(12):2364-5.
View in: PubMed

Sekeres MA, Steensma DP. Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment. Blood. 2009 Sep 24; 114(13):2575-80.
View in: PubMed

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009 Jul 08; (3):CD007303.
View in: PubMed

Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009 Aug 10; 27(23):3842-8.
View in: PubMed

Steensma D, Kantarjian H, Wijermans P. Clinical experience with different dosing schedules of decitabine in patients with myelodysplastic syndromes (MDS). J Clin Oncol. 2009 May 20; 27(15_suppl):7011.
View in: PubMed

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009 May 02; 373(9674):1532-42.
View in: PubMed

Tefferi A, Mesa RA, Pardanani A, Hussein K, Schwager S, Hanson CA, Steensma DP. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not. Am J Hematol. 2009 May; 84(5):265-7.
View in: PubMed

Steensma DP. The Blood of the Lamb. J Clin Oncol. 2009 Jun 01; 27(16):2729-31.
View in: PubMed

Steensma DP. The ordinary miracle of cancer clinical trials. J Clin Oncol. 2009 Apr 10; 27(11):1737-9.
View in: PubMed

Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009 Sep; 33(9):1199-203.
View in: PubMed

Steensma DP, Porcher JC, Litzow MR, Hogan WJ, Arora S, Van Laar ES. Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine. Leuk Res. 2009 Jul; 33(7):e81-2.
View in: PubMed

Steensma DP. Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe? Am J Hematol. 2009 Jan; 84(1):3-5.
View in: PubMed

Li C, Di Pierro E, Brancaleoni V, Cappellini MD, Steensma DP. A novel large deletion and three polymorphisms in the FECH gene associated with erythropoietic protoporphyria. Clin Chem Lab Med. 2009; 47(1):44-6.
View in: PubMed

Steensma DP. The changing classification of myelodysplastic syndromes: what's in a name? Hematology Am Soc Hematol Educ Program. 2009; 645-55.
View in: PubMed

Wardrop D, Steensma DP. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol. 2009 Mar; 144(6):809-17.
View in: PubMed

Steensma DP. Myelodysplasia paranoia: iron as the new radon. Leuk Res. 2009 Sep; 33(9):1158-63.
View in: PubMed

Steensma DP, Tefferi A. Incremental gains and a long road ahead in MDS. Oncology (Williston Park). 2008 Nov 15; 22(12):1352, 1358, 1360.
View in: PubMed

Kumar N, Sandroni P, Steensma DP, Luthra HS, Habermann TM. Polyradiculopathy due to methotrexate-induced ebv-associated lymphoproliferative disorder. Neurology. 2008 Nov 11; 71(20):1644-5.
View in: PubMed

Knoll BM, Letendre L, Steensma DP. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2008 Nov; 83(11):881-3.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. George Herman "Babe" Ruth Jr: baseball star and early participant in a cancer clinical trial. Mayo Clin Proc. 2008 Nov; 83(11):1262.
View in: PubMed

Chen D, Hoyer JD, Ketterling RP, Tefferi A, Steensma DP, Holtan SG, Santana-Davila R, Porrata LF, Dewald GW, Hanson CA. Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q. Leukemia. 2009 Apr; 23(4):796-800.
View in: PubMed

Baumann Kreuziger LM, Steensma DP. RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes. Am J Hematol. 2008 Oct; 83(10):822-3.
View in: PubMed

Steensma DP. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. Am J Hematol. 2008 Sep; 83(9):693-4.
View in: PubMed

Holtan SG, Santana-Davila R, Dewald GW, Khetterling RP, Knudson RA, Hoyer JD, Chen D, Hanson CA, Porrata L, Tefferi A, Steensma DP. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era. Am J Hematol. 2008 Sep; 83(9):708-13.
View in: PubMed

Caudill JS, Imran H, Porcher JC, Steensma DP. Congenital sideroblastic anemia associated with germline polymorphisms reducing expression of FECH. Haematologica. 2008 Oct; 93(10):1582-4.
View in: PubMed

Gangat N, Porcher JC, Steensma DP. Absence of frataxin mutations in refractory anemia with ring sideroblasts (RARS). Leuk Res. 2009 Apr; 33(4):586-7.
View in: PubMed

Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol. 2008 Aug; 83(8):611-3.
View in: PubMed

Dronca RS, Steensma DP. VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia. Nat Clin Pract Oncol. 2008 Sep; 5(9):504-5.
View in: PubMed

Steensma DP. The mosaic of myeloid neoplasia: implications for classification. Leuk Lymphoma. 2008 Jul; 49(7):1228-9.
View in: PubMed

Steensma DP. The art of oncology: when the tumor is not the target. Don't mention it. J Clin Oncol. 2008 Jun 20; 26(18):3083-4.
View in: PubMed

Steensma DP. Review: epoetin and darbepoetin reduce need for blood transfusions but increase risk for thrombosis in patients with cancer. ACP J Club. 2008 Jun 17; 148(4):7.
View in: PubMed

Santana-Davila R, Tefferi A, Holtan SG, Ketterling RP, Dewald GW, Knudson RA, Steensma DP, Chen D, Hoyer JD, Hanson CA. Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases. Leuk Res. 2008 Dec; 32(12):1927-30.
View in: PubMed

Gibbons RJ, Wada T, Fisher CA, Malik N, Mitson MJ, Steensma DP, Fryer A, Goudie DR, Krantz ID, Traeger-Synodinos J. Mutations in the chromatin-associated protein ATRX. Hum Mutat. 2008 Jun; 29(6):796-802.
View in: PubMed

Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Larsen JS, Arora S, Cullen MT, Kantarjian HM. A multicenter phase II trial of the decitabine alternative 5-day dosing regimen: Analysis of efficacy in various subgroups of patients with myelodysplastic syndromes (MDS). J Clin Oncol. 2008 May 20; 26(15_suppl):7032.
View in: PubMed

Godley LA, Steensma DP, Baer MR, Slack JL, Buckstein R, Larsen JS, Arora S, Cullen MT, Kantarjian HM. Cytogenetic responses to a 5-day dosing schedule of decitabine in patients (Pts) with myelodysplastic syndromes (MDS). J Clin Oncol. 2008 May 20; 26(15_suppl):7030.
View in: PubMed

Caudill JS, Porcher JC, Steensma DP. Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes. Leuk Lymphoma. 2008 May; 49(5):989-93.
View in: PubMed

Steensma DP. A premature obituary for erythropoietin analogues. Lancet Oncol. 2008 Apr; 9(4):316.
View in: PubMed

Steensma DP. Investment analysts and the American Society of Hematology. Blood. 2008 Jul 01; 112(1):29-33.
View in: PubMed

Hanson CA, Steensma DP, Hodnefield JM, Nguyen PL, Hoyer JD, Viswanatha DS, Zou Y, Knudson RA, Van Dyke DL, Ketterling RP. Isolated trisomy 15: a clonal chromosome abnormality in bone marrow with doubtful hematologic significance. Am J Clin Pathol. 2008 Mar; 129(3):478-85.
View in: PubMed

Steensma DP, Tefferi A. JAK2 V617F and ringed sideroblasts: not necessarily RARS-T. Blood. 2008 Feb 01; 111(3):1748.
View in: PubMed

Palmer SR, Tefferi A, Hanson CA, Steensma DP. Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts. Br J Haematol. 2008 Mar; 140(6):722-5.
View in: PubMed

Steensma DP. Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol. 2008 Mar 01; 26(7):1022-4.
View in: PubMed

Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008 May; 32(5):691-8.
View in: PubMed

Steensma DP, Porcher JC, Hanson CA, Lathrop CL, Hoyer JD, Lasho TA, Tefferi A, Higgs DR. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders. Br J Haematol. 2007 Nov; 139(3):439-42.
View in: PubMed

Steensma DP. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony. J Support Oncol. 2007 Nov-Dec; 5(10):471-3.
View in: PubMed

Steensma DP. Exacerbation of asthma by Florida "red tide" during an ocean sailing trip. Mayo Clin Proc. 2007 Sep; 82(9):1128-30.
View in: PubMed

White JG, Nichols WL, Steensma DP. Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia II. Cytochemistry. Platelets. 2007 Sep; 18(6):436-50.
View in: PubMed

Santana-Davila R, Holtan SG, Dewald GW, Ketterling RP, Knudson RA, Hanson CA, Steensma DP, Tefferi A. Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution. Leuk Res. 2008 Mar; 32(3):407-11.
View in: PubMed

Steensma DP, Friday BB. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy. Leuk Lymphoma. 2007 Aug; 48(8):1628-9.
View in: PubMed

Steensma DP, Tefferi A. Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc. 2007 Aug; 82(8):958-66.
View in: PubMed

Steensma DP. The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia. Haematologica. 2007 Jun; 92(6):723-7.
View in: PubMed

White JG, Nichols WL, Steensma DP. Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia I ultrastructure. Platelets. 2007 Jun; 18(4):273-83.
View in: PubMed

Steensma DP. Erythropoiesis stimulating agents. BMJ. 2007 Mar 31; 334(7595):648-9.
View in: PubMed

Steensma DP. Processes to activate phase III clinical trials in a cooperative oncology group: the elephant is monstrous. J Clin Oncol. 2007 Mar 20; 25(9):1148; author reply 1148-9.
View in: PubMed

Loprinzi CL, Barton DL, Jatoi A, Sloan J, Martenson J, Steensma D, Rao R, Novotny P, Sood A, Grothey A, Minasian L, Windschitl H. Symptom control trials: a 20-year experience. J Support Oncol. 2007 Mar; 5(3):119-25, 128.
View in: PubMed

Kreuziger LM, Porcher JC, Ketterling RP, Steensma DP. An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome. Leuk Res. 2007 Aug; 31(8):1145-8.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Leopold Ruzicka--1939 Nobel Prize in chemistry. Mayo Clin Proc. 2007 Jan; 82(1):1p preceeding table of contents.
View in: PubMed

Steensma DP, Tefferi A. Risk-based management of myelodysplastic syndrome. Oncology (Williston Park). 2007 Jan; 21(1):43-54; discussion 57-8, 62.
View in: PubMed

Steensma DP, Kyle RA. A history of the kidney in plasma cell disorders. Contrib Nephrol. 2007; 153:5-24.
View in: PubMed

Caudill JS, Sood R, Zehnder JL, Pruthi RK, Steensma DP. Severe coagulation factor V deficiency associated with an interstitial deletion of chromosome 1q. J Thromb Haemost. 2007 Mar; 5(3):626-8.
View in: PubMed

Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007 Mar 15; 109(6):2618-21.
View in: PubMed

Steensma DP, Caudill JS, Pardanani A, McClure RF, Lasho TL, Tefferi A. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count. Haematologica. 2006 Dec; 91(12 Suppl):ECR57.
View in: PubMed

Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol. 2006 Nov; 135(3):405-7.
View in: PubMed

Mesa RA, Tefferi A, Li CY, Steensma DP. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome. Leukemia. 2006 Nov; 20(11):2063-4.
View in: PubMed

Steensma DP. JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn. 2006 Sep; 8(4):397-411; quiz 526.
View in: PubMed

Knox SK, Kurtin PJ, Steensma DP. Isolated splenic sinus histiocytosis (Rosai-Dorfman disease) in association with myelodysplastic syndrome. J Clin Oncol. 2006 Aug 20; 24(24):4027-8.
View in: PubMed

Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia. Leukemia. 2006 Oct; 20(10):1800-8.
View in: PubMed

Steensma DP, Hecksel KA, Porcher JC, Lasho TL. Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts). Leuk Res. 2007 May; 31(5):623-8.
View in: PubMed

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15; 108(10):3472-6.
View in: PubMed

Thurmes PJ, Steensma DP. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis. Eur J Haematol. 2006 Jul; 77(1):57-60.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. William Murphy--Nobel Prize for the treatment of pernicious anemia. Mayo Clin Proc. 2006 Jun; 81(6):726.
View in: PubMed

Steensma DP, McClure RF, Karp JE, Tefferi A, Lasho TL, Powell HL, DeWald GW, Kaufmann SH. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006 Jun; 20(6):971-8.
View in: PubMed

Caudill JS, Sternberg AJ, Li CY, Tefferi A, Lasho TL, Steensma DP. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol. 2006 Jun; 133(6):638-41.
View in: PubMed

Steensma DP, Loprinzi CL. Epoetin alfa and darbepoetin alfa go head to head. J Clin Oncol. 2006 May 20; 24(15):2233-6.
View in: PubMed

Steensma DP. Working against the grain. Ann Intern Med. 2006 May 02; 144(9):697-8.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Stamp vignette on medical science. William F. Giauque--Nobel Prize for low-temperature research. Mayo Clin Proc. 2006 May; 81(5):587.
View in: PubMed

Steensma DP, Tefferi A. Blood vessels everywhere, but so few cells to fill them. Leuk Lymphoma. 2006 Mar; 47(3):377-8.
View in: PubMed

Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Novotny PJ, Tschetter LK, Alberts SR, Hogan TF, Law A, Loprinzi CL. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol. 2006 Mar 01; 24(7):1079-89.
View in: PubMed

Steensma DP, Pardanani A, Stevenson WS, Hoyt R, Kiu H, Grigg AP, Szer J, Juneja S, Hilton DJ, Alexander WS, Roberts AW. More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders. Blood. 2006 Feb 15; 107(4):1733-5; author reply 1735.
View in: PubMed

Costa DB, Fisher CA, Miller KB, Pihan GA, Steensma DP, Gibbons RJ, Higgs DR. A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndrome. Eur J Haematol. 2006 May; 76(5):432-5, 453.
View in: PubMed

Steensma DP. Luis Walter Alvarez: another "Mayo-trained" Nobel Laureate. Mayo Clin Proc. 2006 Feb; 81(2):241-4.
View in: PubMed

Nelson ME, Steensma DP. JAK2 V617F in myeloid disorders: what do we know now, and where are we headed? Leuk Lymphoma. 2006 Feb; 47(2):177-94.
View in: PubMed

Steensma DP. Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. Leuk Res. 2006 Oct; 30(10):1227-33.
View in: PubMed

Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc. 2006 Jan; 81(1):104-30.
View in: PubMed

Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia. 2005 Dec; 19(12):2195-202.
View in: PubMed

Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol. 2005 Nov; 131(3):320-8.
View in: PubMed

Nelson ME, Thurmes PJ, Hoyer JD, Steensma DP. A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome. Haematologica. 2005 Nov; 90(11):1463-70.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Sir Charles Sherrington--"The William Harvey of the nervous system". Mayo Clin Proc. 2005 Oct; 80(10):1266.
View in: PubMed

Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol. 2005 Oct; 131(2):166-71.
View in: PubMed

Steensma DP, Witzig TE. Does treatment with recombinant human erythropoietin affect the survival of anemic patients with cancer? Nat Clin Pract Oncol. 2005 Sep; 2(9):444-5.
View in: PubMed

Loprinzi C, Steensma D. The questions of prognosis. J Support Oncol. 2005 Sep-Oct; 3(5):340-1.
View in: PubMed

Steensma DP, Loprinzi CL. Erythropoietin use in cancer patients: a matter of life and death? J Clin Oncol. 2005 Sep 01; 23(25):5865-8.
View in: PubMed

Steensma DP, Molina R, Sloan JA, Nikcevich DA, Schaefer PL, Rowland KM, Dentchev T, Tschetter LK, Novotny PJ, Loprinzi CL. A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2. J Clin Oncol. 2005 Jun; 23(16_suppl):8031.
View in: PubMed

Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc. 2005 May; 80(5):681-98.
View in: PubMed

Steensma DP. Polycythemia vera: plethora, from prehistory to present. Curr Hematol Rep. 2005 May; 4(3):230-4.
View in: PubMed

Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005 Aug 15; 106(4):1207-9.
View in: PubMed

Steensma DP, Shampo MA, Kyle RA. Cecilia Makiwane--pioneer African nurse. Mayo Clin Proc. 2005 Apr; 80(4):449.
View in: PubMed

Shanafelt TD, Novotny P, Johnson ME, Zhao X, Steensma DP, Lacy MQ, Rubin J, Sloan J. The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment Group. Oncology. 2005; 68(1):23-32.
View in: PubMed

Steensma DP. Down syndrome in Down House: trisomy 21, GATA1 mutations, and Charles Darwin. Blood. 2005 Mar 15; 105(6):2614-6.
View in: PubMed

Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia. Eur J Haematol. 2005 Jan; 74(1):47-53.
View in: PubMed

Steensma DP. Northwoods elegy. Ann Intern Med. 2004 Oct 05; 141(7):573-4.
View in: PubMed

Shampo MA, Kyle RA, Steensma DP. Ferid Murad--1998 Nobel laureate for nitric oxide research. Mayo Clin Proc. 2004 Oct; 79(10):1230.
View in: PubMed

Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2005 Jan 15; 105(2):443-52.
View in: PubMed

Fisher C, Steensma D, Janmohamed R, Kaczmarski R, Reilly JT, Vyas P. Absence of mutations in the key megakaryocyte transcriptional regulator FOG-1 in patients with idiopathic myelofibrosis. Br J Haematol. 2004 Sep; 126(5):750-2.
View in: PubMed

Steensma DP. Myelodysplasia, megakaryocytes, and methylation. Leuk Res. 2004 Aug; 28(8):775-6.
View in: PubMed

Steensma DP. Reassurance. J Clin Oncol. 2004 Aug 01; 22(15):3196-8.
View in: PubMed

Steensma DP. Management of anemia in patients with cancer. Curr Oncol Rep. 2004 Jul; 6(4):297-304.
View in: PubMed

Steensma DP. The symbol of modern medicine. Ann Intern Med. 2004 Feb 17; 140(4):311; author reply 311-2.
View in: PubMed

Steensma DP. Enough already of the word "robust"! Blood. 2004 Jan 15; 103(2):746-7.
View in: PubMed

Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood. 2004 Mar 15; 103(6):2019-26.
View in: PubMed

Steensma DP, Viprakasit V, Hendrick A, Goff DK, Leach J, Gibbons RJ, Higgs DR. Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome. Blood. 2004 Feb 15; 103(4):1518-20.
View in: PubMed

Mesa RA, Steensma DP, Hoyer J, Ketterling RP. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate. Br J Haematol. 2003 Oct; 123(2):366-7.
View in: PubMed

Steensma DP, Tefferi A, Li CY. Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Leuk Res. 2003 Sep; 27(9):775-82.
View in: PubMed

Steensma DP, Mesa RA, Reeder TL, Tefferi A, Kaufmann SH. Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow. Haematologica. 2003 Sep; 88(9):1072-4.
View in: PubMed

Steensma DP. The In-Training Examination in Internal Medicine. Ann Intern Med. 2003 Jun 17; 138(12):1009; author reply 1010-1.
View in: PubMed

Steensma DP. The narrow path. J Clin Oncol. 2003 May 01; 21(9 Suppl):57s-60s; discussion 60s.
View in: PubMed

Steensma DP. Why me? J Clin Oncol. 2003 May 01; 21(9 Suppl):64s-66s.
View in: PubMed

Daugherty CK, Steensma DP. Overcoming obstacles to hospice care: an ethical examination of inertia and inaction. J Clin Oncol. 2003 May 01; 21(9 Suppl):42s-45s.
View in: PubMed

Steensma DP. Submitting to autonomy. J Clin Oncol. 2003 May 01; 21(9 Suppl):62s-63s.
View in: PubMed

Steensma DP. The chronic myeloproliferative disorders: an historical perspective. Curr Hematol Rep. 2003 May; 2(3):221-30.
View in: PubMed

Steensma DP, Dewald GW, Hodnefield JM, Tefferi A, Hanson CA. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? Leuk Res. 2003 Mar; 27(3):235-42.
View in: PubMed

Steensma DP. "Pawn Ball Megakaryocytes": from the marvellous medici and dear Old Saint Nick to the unsanctified marrow of myelodysplasia. Hematology. 2003 Feb; 8(1):11-8.
View in: PubMed

Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003 Feb; 27(2):95-120.
View in: PubMed

Steensma DP. The kiss of death: a severe allergic reaction to a shellfish induced by a good-night kiss. Mayo Clin Proc. 2003 Feb; 78(2):221-2.
View in: PubMed

Steensma DP, Timm M, Witzig TE. Flow cytometric methods for detection and quantification of apoptosis. Methods Mol Med. 2003; 85:323-32.
View in: PubMed

Steensma DP. Eureka moments. Pharos Alpha Omega Alpha Honor Med Soc. 2003; 66(4):43.
View in: PubMed

Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003 Apr 01; 101(7):2534-41.
View in: PubMed

Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 2003 Mar 15; 101(6):2156-8.
View in: PubMed

Steensma DP. John Calvin and Michael Servetus: tragic clash of reformer and radical physician. Scalpel Tongs. 2002 Oct-Dec; 46(1):14-9.
View in: PubMed

Steensma DP. The other résumé. Ann Intern Med. 2002 Oct 01; 137(7):623.
View in: PubMed

Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002 Sep; 118(3):813-6.
View in: PubMed

Daugherty CK, Steensma DP. Overcoming obstacles to hospice care: an ethical examination of inertia and inaction. J Clin Oncol. 2002 Jun 01; 20(11):2752-5.
View in: PubMed

Tefferi A, Mesa RA, Gray LA, Steensma DP, Camoriano JK, Elliott MA, Pardanani A, Ansell SM, Call TG, Colon-Otero G, Schroeder G, Hanson CA, Dewald GW, Kaufmann SH. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood. 2002 May 15; 99(10):3854-6.
View in: PubMed

Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood. 2002 Mar 15; 99(6):2252-4.
View in: PubMed

Steensma DP. Why me? J Clin Oncol. 2002 Feb 01; 20(3):873-5.
View in: PubMed

Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol. 2002; 108(2):55-65.
View in: PubMed

Steensma DP, Harrison CN, Tefferi A. Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1243-53.
View in: PubMed

Steensma DP, Tefferi A. Myelodysplastic syndrome and pregnancy: the Mayo Clinic experience. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1229-34.
View in: PubMed

Steensma DP, Hanson CA, Letendre L, Tefferi A. Myelodysplasia with fibrosis: a distinct entity? Leuk Res. 2001 Oct; 25(10):829-38.
View in: PubMed

Steensma DP, Letendre L, Tefferi A. Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed. Blood. 2001 May 15; 97(10):3321-2.
View in: PubMed

Steensma DP, Gertz MA, Greipp PR, Kyle RA, Lacy MQ, Lust JA, Offord JR, Plevak MF, Therneau TM, Witzig TE. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood. 2001 Apr 15; 97(8):2522-3.
View in: PubMed

Steensma DP. The narrow path. J Clin Oncol. 2001 Apr 01; 19(7):2102-5.
View in: PubMed

Steensma DP, Hoyer JD, Fairbanks VF. Hereditary red blood cell disorders in middle eastern patients. Mayo Clin Proc. 2001 Mar; 76(3):285-93.
View in: PubMed

Tefferi A, Elliott MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, Schroeder G, Letendre L. Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res. 2001 Feb; 25(2):183-5.
View in: PubMed

Steensma DP. "Congo" red: out of Africa? Arch Pathol Lab Med. 2001 Feb; 125(2):250-2.
View in: PubMed

Steensma DP. Submitting to autonomy. J Clin Oncol. 2000 Nov 01; 18(21):3736-7.
View in: PubMed

Steensma DP, Loprinzi CL. The art and science of prognosis in patients with advanced cancer. Eur J Cancer. 2000 Oct; 36(16):2025-7.
View in: PubMed

Steensma DP, Tefferi A, Weiler CR. Autoimmune hemolytic anemia in a patient with autosomal dominant chronic mucocutaneous candidiasis. Mayo Clin Proc. 2000 Aug; 75(8):853-5.
View in: PubMed

Steensma DP. Sister (Mary) Joseph's nodule. Ann Intern Med. 2000 Aug 01; 133(3):237.
View in: PubMed

Habermann TM, Steensma DP. Lymphadenopathy. Mayo Clin Proc. 2000 Jul; 75(7):723-32.
View in: PubMed

Steensma DP, Morice WG. Littoral cell angioma associated with portal hypertension and resected colon cancer. Acta Haematol. 2000; 104(2-3):131-4.
View in: PubMed

Steensma DP, Witzig TE. Elevated serum LDH in patients with non-Hodgkin's lymphoma: not always an ominous sign. Br J Haematol. 1999 Nov; 107(2):463-4.
View in: PubMed

Steensma DP. Fifty years of Tart cells. Mayo Clin Proc. 1999 Sep; 74(9):936-8.
View in: PubMed

Steensma DP, Matteson EL. 80-year-old woman with dizziness. Mayo Clin Proc. 1997 Aug; 72(8):781-4.
View in: PubMed

Top